Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SREBF2 | Q12772 | 8/20 | 0.49 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NOS2 | P35228 | 3/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779666 | 0.88 | NOS2 (0.50) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| SCHEMBL645891 | 0.88 | NOS2 (0.50) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| Hydrochloric Acid SCHEMBL28783127 | 0.86 | NOS2 (0.49) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| Iodide SCHEMBL29869193 | 0.86 | NOS2 (0.49) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| Phosphine SCHEMBL27841866 | 0.86 | NOS2 (0.49) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| SCHEMBL921653 | 0.86 | KDM4E (0.47) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| SCHEMBL29473921 | 0.86 | KDM4E (0.47) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| SCHEMBL1030077 | 0.86 | KDM4E (0.47) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| SCHEMBL2547957 | 0.84 | KCNH2 (0.48) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| SCHEMBL2551597 | 0.84 | KCNH2 (0.48) | KDM4ELMNACYP3A4TSHRSREBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020132700-A1 | METHODS OF USING INHIBITORS OF SREBP IN COMBINATION WITH NICLOSAMIDE AND ANALOGS THEREOF | Fgh Biotech Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-3038622-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9637477-B2 | Therapeutic substituted pyrroles | ALLERGAN, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150336940-A1 | THERAPEUTIC SUBSTITUTED PYRROLES | ALLERGAN, INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| US-7985765-B2 | Therapeutic substituted pyrroles | ALLERGAN, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| WO-2010089292-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100048664-A1 | THERAPEUTIC SUBSTITUTED PYRROLES | ALLERGAN, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2009088986-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009046448-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336940-A1 | THERAPEUTIC SUBSTITUTED PYRROLES | PTGS2, PTGES2, PTGIS | KDM4E 1953/4885LMNA 3216/4885CYP3A4 3521/4885 |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRAS, VHL, ESRRB | KDM4E 3356/4885LMNA 2671/4885CYP3A4 2057/4885 |
| US-20100048664-A1 | THERAPEUTIC SUBSTITUTED PYRROLES | GOT2, FARS2, THPO | KDM4E 2057/4885LMNA 4127/4885CYP3A4 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.